164 related articles for article (PubMed ID: 37705354)
1. A review of technological developments in lipid nanoparticle application for mRNA vaccination.
Yeh TF; Lin C; Sung HC
Hum Vaccin Immunother; 2023 Aug; 19(2):2256040. PubMed ID: 37705354
[TBL] [Abstract][Full Text] [Related]
2. Current status and patent prospective of lipid nanoparticle for mRNA delivery.
Zhang HL
Expert Opin Ther Pat; 2023 Feb; 33(2):125-131. PubMed ID: 36958374
[TBL] [Abstract][Full Text] [Related]
3. Lipid Nanoparticles─From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement.
Tenchov R; Bird R; Curtze AE; Zhou Q
ACS Nano; 2021 Nov; 15(11):16982-17015. PubMed ID: 34181394
[TBL] [Abstract][Full Text] [Related]
4. Current Developments and Challenges of mRNA Vaccines.
Chen J; Chen J; Xu Q
Annu Rev Biomed Eng; 2022 Jun; 24():85-109. PubMed ID: 35231177
[TBL] [Abstract][Full Text] [Related]
5. Investigating Generation of Antibodies against the Lipid Nanoparticle Vector Following COVID-19 Vaccination with an mRNA Vaccine.
Münter R; Sørensen E; Hasselbalch RB; Christensen E; Nielsen SD; Garred P; Ostrowski SR; Bundgaard H; Iversen KK; Andresen TL; Larsen JB
Mol Pharm; 2023 Jul; 20(7):3356-3366. PubMed ID: 36952227
[TBL] [Abstract][Full Text] [Related]
6. Development of a high-throughput platform for screening lipid nanoparticles for mRNA delivery.
Cui L; Pereira S; Sonzini S; van Pelt S; Romanelli SM; Liang L; Ulkoski D; Krishnamurthy VR; Brannigan E; Brankin C; Desai AS
Nanoscale; 2022 Jan; 14(4):1480-1491. PubMed ID: 35024714
[TBL] [Abstract][Full Text] [Related]
7. Effects of PEG antibodies on in vivo performance of LNP-mRNA vaccines.
Yang M; Zhang Z; Jin P; Jiang K; Xu Y; Pan F; Tian K; Yuan Z; Liu XE; Fu J; Wang B; Yan H; Zhan C; Zhang Z
Int J Pharm; 2024 Jan; 650():123695. PubMed ID: 38081560
[TBL] [Abstract][Full Text] [Related]
8. Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine.
Ju Y; Lee WS; Pilkington EH; Kelly HG; Li S; Selva KJ; Wragg KM; Subbarao K; Nguyen THO; Rowntree LC; Allen LF; Bond K; Williamson DA; Truong NP; Plebanski M; Kedzierska K; Mahanty S; Chung AW; Caruso F; Wheatley AK; Juno JA; Kent SJ
ACS Nano; 2022 Aug; 16(8):11769-11780. PubMed ID: 35758934
[TBL] [Abstract][Full Text] [Related]
9. Low energy nebulization preserves integrity of SARS-CoV-2 mRNA vaccines for respiratory delivery.
van Rijn CJM; Vlaming KE; Bem RA; Dekker RJ; Poortinga A; Breit T; van Leeuwen S; Ensink WA; van Wijnbergen K; van Hamme JL; Bonn D; Geijtenbeek TBH
Sci Rep; 2023 May; 13(1):8851. PubMed ID: 37258559
[TBL] [Abstract][Full Text] [Related]
10. A Case Study: Analysis of Patents on Coronaviruses and Covid-19 for Technological Assessment and Future Research.
Musyuni P; Aggarwal G; Nagpal M; Goyal RK
Curr Pharm Des; 2021; 27(3):423-439. PubMed ID: 32693757
[TBL] [Abstract][Full Text] [Related]
11. Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV
Valentin A; Bergamaschi C; Rosati M; Angel M; Burns R; Agarwal M; Gergen J; Petsch B; Oostvogels L; Loeliger E; Chew KW; Deeks SG; Mullins JI; Pavlakis GN; Felber BK
Front Immunol; 2022; 13():945706. PubMed ID: 35935984
[TBL] [Abstract][Full Text] [Related]
12. Chemistry of Lipid Nanoparticles for RNA Delivery.
Eygeris Y; Gupta M; Kim J; Sahay G
Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
[TBL] [Abstract][Full Text] [Related]
13. The global mRNA vaccine patent landscape.
Li M; Ren J; Si X; Sun Z; Wang P; Zhang X; Liu K; Wei B
Hum Vaccin Immunother; 2022 Nov; 18(6):2095837. PubMed ID: 35797353
[TBL] [Abstract][Full Text] [Related]
14. Innate immune mechanisms of mRNA vaccines.
Verbeke R; Hogan MJ; Loré K; Pardi N
Immunity; 2022 Nov; 55(11):1993-2005. PubMed ID: 36351374
[TBL] [Abstract][Full Text] [Related]
15. A systematic and thematic analysis of the top 100 cited articles on mRNA vaccine indexed in Scopus database.
Musa HH; Musa TH
Hum Vaccin Immunother; 2022 Nov; 18(6):2135927. PubMed ID: 36328513
[TBL] [Abstract][Full Text] [Related]
16. mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells.
Bevers S; Kooijmans SAA; Van de Velde E; Evers MJW; Seghers S; Gitz-Francois JJJM; van Kronenburg NCH; Fens MHAM; Mastrobattista E; Hassler L; Sork H; Lehto T; Ahmed KE; El Andaloussi S; Fiedler K; Breckpot K; Maes M; Van Hoorick D; Bastogne T; Schiffelers RM; De Koker S
Mol Ther; 2022 Sep; 30(9):3078-3094. PubMed ID: 35821637
[TBL] [Abstract][Full Text] [Related]
17. Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs.
Suzuki Y; Ishihara H
Drug Metab Pharmacokinet; 2021 Dec; 41():100424. PubMed ID: 34757287
[TBL] [Abstract][Full Text] [Related]
18. Design Strategies for and Stability of mRNA-Lipid Nanoparticle COVID-19 Vaccines.
Liu T; Tian Y; Zheng A; Cui C
Polymers (Basel); 2022 Oct; 14(19):. PubMed ID: 36236141
[TBL] [Abstract][Full Text] [Related]
19. Clinical Development of mRNA Vaccines: Challenges and Opportunities.
August A; Brito L; Paris R; Zaks T
Curr Top Microbiol Immunol; 2022; 440():167-186. PubMed ID: 35906319
[TBL] [Abstract][Full Text] [Related]
20. Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy.
Zong Y; Lin Y; Wei T; Cheng Q
Adv Mater; 2023 Dec; 35(51):e2303261. PubMed ID: 37196221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
